Kaidi Yin, Lili Deng, Wen Liu^*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.075185 - 21 May 2026

Abstract Objectives: Although claudin-1 (CLDN1) interacts with Cluster of Differentiation 81 (CD81) in various cell types, the specific mechanism underlying this interaction and its functional implications in colorectal cancer (CRC) cells remain poorly understood. This study outlines the regulatory role of CLDN1 in CRC cell tumorigenicity through its interaction with CD81, elucidating the underlying signaling cascade. Methods: Changes in the expression of CLDN1 and CD81, as well as their correlation with the survival of CRC patients, were analyzed using samples from The Cancer Genome Atlas database, the Kaplan‒Meier plotter database, and tissue microarrays. CLDN1 and CD81 were… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.081623 - 22 April 2026

Abstract This article has no abstract. More >

Munro Matthew James^1,*, López Vásquez Clara Elena^1,2, Wickremesekera Agadha³, Chan Alex Ho Chuen¹, Gray Clint Lee^1,4,5,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074958 - 22 April 2026

Abstract Objective: Meningioma is the most common primary brain tumour. Invasion into the brain is a diagnostic feature of grade II meningiomas and is associated with recurrence and poor prognosis. Mebendazole is a microtubule inhibitor typically prescribed as an anthelmintic. However, it has the potential to be repurposed for cancer treatment. Here, we aimed to assess the ability of mebendazole to inhibit meningioma cell invasion. Methods: Primary patient-derived meningioma cell lines were cultured as 3D spheroids and embedded in an extracellular matrix-like matrix as an in vitro model of invasion. Mebendazole-treated and untreated control spheroids were analysed… More >

Haojie Yang^1,2,#, Zicong Tan^1,2,#, Zihao Liu^3,#, Kang Chen^1,2, Ning Liufu^1,2,*, Fengtao Ji^1,2,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.073081 - 22 April 2026

Abstract Background: Circular RNAs (circRNAs) play a crucial role in the progression of malignant tumors such as breast cancer. Methods: A circRNA microarray was used to detect key circRNAs in breast cancer. Expression of Circ72688 was verified by quantitative reverse transcription PCR (qRT-PCR) and fluorescence in situ hybridization (FISH) assay. Transwell assay and in vivo assay were conducted to prove the function of Circ72688. Exploring the downstream mechanism, dual-luciferase reporter assay, western blotting, and tissue microarray were performed. Results: We sequenced and identified a circRNA, hsa-circ-0072688, also known as Circ72688. Our research found that Circ72688 enhanced tumor metastasis both More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.081284 - 23 March 2026

Abstract This article has no abstract. More >

Yin-Lun Chang^1,2, Hao-Lun Luo¹, Jei-Ming Peng^3,*, Chang-Chun Hsiao^2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070837 - 23 March 2026

Abstract Background: Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with high recurrence rates. Lymphovascular invasion (LVI) predicts a poor prognosis, yet its molecular drivers remain unclear. BOC cell adhesion-associated, oncogene-regulated (BOC, also known as Brother of CDO [Cell adhesion molecule-Related/Down-regulated by Oncogenes]), a hedgehog-related cell surface receptor, may serve as a biomarker for tumor progression and chemotherapy response. The study aimed to investigate the role of BOC in UTUC and its potential to predict LVI and chemotherapy response. Methods: Sequencing (RNA-seq) of 10 stage III UTUC, treatment-naïve, fresh tissue samples identified BOC as a… More >

Eva Donck^1,*, Sofie Verbeke², Pieter De Visschere³, Valérie Fonteyne⁴, Charles Van Praet¹, Kathia De Man⁵, Nicolaas Lumen¹

Canadian Journal of Urology, Vol.33, No.1, pp. 83-92, 2026, DOI:10.32604/cju.2025.068589 - 28 February 2026

Abstract Objectives: PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography) offers improved accuracy in detecting lymph node invasion (LNI) in prostate cancer (PC) patients, potentially reducing the need for extended pelvic lymph node dissection (ePLND). This study aims to evaluate a patient-tailored care pathway in which ePLND is performed only in patients with unfavorable intermediate- or high-risk PC who are deemed at risk for LNI based on PSMA PET/CT findings. Methods: In this interventional cohort study, 81 patients were managed according to the new care pathway. ePLND was omitted in cases of negative PSMA PET/CT… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.080053 - 24 February 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.078459 - 19 January 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077269 - 30 December 2025

Abstract This article has no abstract. More >